Literature DB >> 29522162

Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations.

Y Taniguchi1, A Tamiya2, S Ishii2, S Atagi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29522162     DOI： 10.1093/annonc/mdy087

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Giorgia Guaitoli; Marcello Tiseo; Massimo Di Maio; Luc Friboulet; Francesco Facchinetti
Journal:  Transl Lung Cancer Res       Date:  2021-06

2.  Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report.

Authors:  Jie Li; Junrong Yan; Ran Cao; Guanjun Du; Guofang Zhao
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

3.  Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.

Authors:  Meng Zhang; Ligong Nie; Yuan Cheng
Journal:  Thorac Cancer       Date:  2021-08-11       Impact factor: 3.500
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.